InVEST Program for High Risk for Psychosis
(InVEST Trial)
Trial Summary
What is the purpose of this trial?
The purpose of this study is to test the efficacy of InVEST (Individualized Vocational and Educational Support and Training) for CHR-P (clinical high risk for psychosis) to address specific role functioning difficulties associated with the CHR-P phase. Our specific goals are: 1. Part 1: Preliminary open trial of InVEST (n = 8) to collect preliminary feasibility and acceptability data by providing the intervention, administering assessments, and collecting focus group and self-report feedback from open trial participants. The open trial phase will help to refine recruitment approaches and to modify the treatment manual as needed. 2. Part 2: Preliminary randomized controlled trial of InVEST vs. Delayed InVEST (DI) to explore preliminary evidence of efficacy of InVEST vs. DI (n = 30). The investigators hope to gain understanding of the feasibility of InVEST and the study's assessment procedures, and to gain a preliminary understanding of the intervention's efficacy for functioning difficulties experienced by young people at CHR-P.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the InVEST treatment for high risk for psychosis?
Is the InVEST Program for High Risk for Psychosis safe for humans?
The research articles do not provide specific safety data for the InVEST Program or its related interventions, but they do mention that early psychosis intervention programs, which include components like supported employment and education, are widely implemented and recommended in guidelines, suggesting a general acceptance of their safety in practice.14567
How is the InVEST treatment different from other treatments for high risk for psychosis?
Research Team
Michelle Friedman-Yakoobian, PHD
Principal Investigator
Department of Psychiatry at BIDMC - a major teaching hospital of Harvard Medical School
Eligibility Criteria
This trial is for English-speaking individuals aged 12-18 who are at high risk for psychosis, as determined by a specific interview process. They must have some difficulty with daily roles and their parent must agree to allow communication between the trial coaches and treatment providers.Inclusion Criteria
Exclusion Criteria
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
Development Phase/Open Trial
Preliminary open trial of InVEST to collect feasibility and acceptability data, refine recruitment approaches, and modify the treatment manual.
Pilot Study Phase
Randomized trial comparing InVEST treatment vs. Delayed InVEST to explore preliminary evidence of efficacy.
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- InVEST (Behavioral Intervention)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Beth Israel Deaconess Medical Center
Lead Sponsor
Dr. Kevin Tabb
Beth Israel Deaconess Medical Center
Chief Executive Officer since 2021
MD from Hebrew University Hadassah Medical School
Dr. Chi Chang Daniel Siao
Beth Israel Deaconess Medical Center
Chief Medical Officer since 2023
MD from King George’s Medical University